- Home
- / Sellas Life Sciences
Sellas Life Sciences
Stock Price
$1.2
2024-10-29
Market Capitalization
$79.1 M
2024-10-29
Revenue
$1 M
FY, 2022
Sellas Life Sciences Summary
Company Summary
- Overview
- SELLAS Life Sciences is a clinical biopharmaceutical company focused on the development of cancer immunotherapies. Its lead product candidate, galinpepimut-S (GPS), is a cancer immunotherapeutic agent that targets a spectrum of hematologic cancers and solid tumor indications. The company was formed as a result of a merger between Galena Biopharma and SELLAS Life Sciences Group Ltd.
- Type
- Public
- Status
- Active
- Founded
- 2006
- HQ
- New York, NY, US | view all locations
- Cybersecurity rating
Table of Contents
Key People
Dragan Cicic, Senior Vice President, Clinical Development
Barbara A. Wood, Executive Vice President, General Counsel and Corporate Secretary
John T. Burns, Vice President Finance, Corporate Controller and Interim Principal Accounting Officer
LocationsView all
2 locations detected
New York, NY HQ
United States
7 Times Square # 2503
New York, NY
United States
15 W 38th St #10th
Sellas Life Sciences Financials
Summary Financials
- Net income (Q1, 2026)
- ($8.4M)
- Cash (Q1, 2026)
- $107.1M
- EBIT (Q1, 2026)
- ($9.3M)
- Enterprise value
- ($27.1M)